Yüklüyor......
The cost-effectiveness of a modestly effective HIV vaccine in the United States
BACKGROUND: The recent RV144 clinical trial showed that an ALVAC/AIDSVAX prime-boost HIV vaccine regimen may confer partial immunity in recipients and reduce transmission by 31%. Trial data suggest that efficacy may initially exceed 70% but decline over the following 3.5 years. Estimating the potent...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2011
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3156325/ https://ncbi.nlm.nih.gov/pubmed/21510996 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2011.04.013 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|